Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


South African centre to research MDR-TB (multidrug-resistant tuberculosis) care:

This article was originally published in Clinica

Executive Summary

South Africa has opened an airborne-infection research facility aimed at studying the transmission of multidrug-resistant tuberculosis (MDR-TB), amid concern at its high incidence and mortality and the need to improve infection control and disease management. The HJE Schultz Santa Centre in Witbank is a joint venture involving South Africa's Medical Research Council, the US Centers for Disease Control and Prevention and the Harvard School of Public Health, among others. The development of MDR-TB is attributed to poorly managed TB - resulting from inadequately monitored or early termination of treatment. The new centre will seek to improve disease management policy. MDR-TB is associated with South Africa's high AIDS-related mortality, and is 100 times more costly to treat than TB, according to Dr Karin Weyer, head of TB at the MRC.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts